Show simple item record

dc.contributor.authorParisinos, CA
dc.contributor.authorWilman, HR
dc.contributor.authorThomas, EL
dc.contributor.authorKelly, M
dc.contributor.authorNicholls, RC
dc.contributor.authorMcGonigle, J
dc.contributor.authorNeubauer, S
dc.contributor.authorHingorani, AD
dc.contributor.authorPatel, RS
dc.contributor.authorHemingway, H
dc.contributor.authorBell, JD
dc.contributor.authorBanerjee, R
dc.contributor.authorYaghootkar, H
dc.date.accessioned2020-05-26T07:42:05Z
dc.date.issued2020-04-02
dc.description.abstractBACKGROUND: A non-invasive method to grade the severity of steatohepatitis and liver fibrosis is magnetic resonance imaging (MRI) based corrected T1 (cT1). We aimed to identify genetic variants influencing liver cT1 and use genetics to understand mechanisms underlying liver fibroinflammatory disease and its link with other metabolic traits and diseases. METHODS: First, we performed a genome-wide association study (GWAS) in 14,440 Europeans in UK Biobank with liver cT1 measures. Second, we explored the effects of the cT1 variants on liver blood tests, and a range of metabolic traits and diseases. Third, we used Mendelian randomisation to test the causal effects of 24 predominantly metabolic traits on liver cT1 measures. RESULTS: We identified six independent genetic variants associated with liver cT1 that reached GWAS significance threshold (p<5x10-8). Four of the variants (rs75935921 in SLC30A10, rs13107325 in SLC39A8, rs58542926 in TM6SF2, rs738409 in PNPLA3) were also associated with elevated transaminases and had variable effects on liver fat and other metabolic traits. Insulin resistance, type 2 diabetes, non-alcoholic fatty liver and BMI were causally associated with elevated cT1 whilst favourable adiposity (instrumented by variants associated with higher adiposity but lower risk of cardiometabolic disease and lower liver fat) was found to be protective. CONCLUSION: The association between two metal ion transporters and cT1 indicates an important new mechanism in steatohepatitis. Future studies are needed to determine whether interventions targeting the identified transporters might prevent liver disease in at risk individuals.en_GB
dc.description.sponsorshipDiabetes UKen_GB
dc.description.sponsorshipWellcome Trusten_GB
dc.description.sponsorshipInnovate UK Knowledge Transfer Partnershipen_GB
dc.identifier.citationPublished online 2 April 2020en_GB
dc.identifier.doi10.1016/j.jhep.2020.03.032
dc.identifier.grantnumber17/0005594en_GB
dc.identifier.grantnumber206274/Z/17/Zen_GB
dc.identifier.grantnumberKTP10271en_GB
dc.identifier.otherS0168-8278(20)30194-X
dc.identifier.urihttp://hdl.handle.net/10871/121149
dc.language.isoenen_GB
dc.publisherElsevieren_GB
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pubmed/32247823en_GB
dc.rights© 2020 European Association for the Study of the Liver. Published by Elsevier B.V. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).en_GB
dc.subjectMagnetic resonance imagingen_GB
dc.subjectcT1en_GB
dc.subjectfibrosisen_GB
dc.subjectgenome-wide association studyen_GB
dc.subjectmetabolic syndromeen_GB
dc.subjectsteatohepatitisen_GB
dc.titleGenome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis.en_GB
dc.typeArticleen_GB
dc.date.available2020-05-26T07:42:05Z
exeter.place-of-publicationNetherlandsen_GB
dc.descriptionThis is the final version. Available from Elsevier via the DOI in this record. en_GB
dc.descriptionFull data including individual cT1 and PDFF measures will be returned to UK Biobank and made publicly available via application (amsportal.ukbiobank.ac.uk).en_GB
dc.identifier.journalJournal of Hepatologyen_GB
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_GB
dcterms.dateAccepted2020-03-19
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2020-04-02
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2020-05-26T07:38:03Z
refterms.versionFCDVoR
refterms.dateFOA2020-05-26T07:42:08Z
refterms.panelAen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2020 European Association for the Study of the Liver. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
Except where otherwise noted, this item's licence is described as © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).